These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
465 related articles for article (PubMed ID: 16951329)
1. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. Ly D; Mi QS; Hussain S; Delovitch TL J Immunol; 2006 Sep; 177(6):3695-704. PubMed ID: 16951329 [TBL] [Abstract][Full Text] [Related]
2. A Novel Liposome Formulation Carrying Both an Insulin Peptide and a Ligand for Invariant Natural Killer T Cells Induces Accumulation of Regulatory T Cells to Islets in Nonobese Diabetic Mice. Akimoto H; Fukuda-Kawaguchi E; Duramad O; Ishii Y; Tanabe K J Diabetes Res; 2019; 2019():9430473. PubMed ID: 31781669 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells. Mi QS; Ly D; Zucker P; McGarry M; Delovitch TL Diabetes; 2004 May; 53(5):1303-10. PubMed ID: 15111500 [TBL] [Abstract][Full Text] [Related]
5. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. Gregori S; Giarratana N; Smiroldo S; Adorini L J Immunol; 2003 Oct; 171(8):4040-7. PubMed ID: 14530324 [TBL] [Abstract][Full Text] [Related]
6. Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells. Mellanby RJ; Thomas D; Phillips JM; Cooke A Immunology; 2007 May; 121(1):15-28. PubMed ID: 17428252 [TBL] [Abstract][Full Text] [Related]
7. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in prevention of autoimmune diabetes in non-obese diabetic mice treated with alpha-galactosylceramide. Li W; Ji F; Zhang Y; Wang Y; Yang N; Ge H; Wang F Acta Biochim Biophys Sin (Shanghai); 2008 May; 40(5):381-90. PubMed ID: 18465023 [TBL] [Abstract][Full Text] [Related]
8. A regulatory CD4+ T cell subset in the BB rat model of autoimmune diabetes expresses neither CD25 nor Foxp3. Hillebrands JL; Whalen B; Visser JT; Koning J; Bishop KD; Leif J; Rozing J; Mordes JP; Greiner DL; Rossini AA J Immunol; 2006 Dec; 177(11):7820-32. PubMed ID: 17114453 [TBL] [Abstract][Full Text] [Related]
9. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711 [TBL] [Abstract][Full Text] [Related]
10. The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR. Pyz E; Naidenko O; Miyake S; Yamamura T; Berberich I; Cardell S; Kronenberg M; Herrmann T J Immunol; 2006 Jun; 176(12):7447-55. PubMed ID: 16751390 [TBL] [Abstract][Full Text] [Related]
11. IL-15 promotes regulatory T cell function and protects against diabetes development in NK-depleted NOD mice. Xia J; Liu W; Hu B; Tian Z; Yang Y Clin Immunol; 2010 Feb; 134(2):130-9. PubMed ID: 19875339 [TBL] [Abstract][Full Text] [Related]
12. Impact of activated invariant natural killer T cells on the expansion of regulatory T cell precursors in murine thymocytes in vitro. Katsumata H; Ikemiyagi M; Hirai T; Kanzawa T; Ishii R; Miyairi S; Fukuda H; Saiga K; Okumi M; Ishii Y; Yokoo T; Tanabe K Immunol Lett; 2019 Feb; 206():41-48. PubMed ID: 30503823 [TBL] [Abstract][Full Text] [Related]
13. Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Miellot A; Zhu R; Diem S; Boissier MC; Herbelin A; Bessis N Eur J Immunol; 2005 Dec; 35(12):3704-13. PubMed ID: 16304639 [TBL] [Abstract][Full Text] [Related]
14. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. Szanya V; Ermann J; Taylor C; Holness C; Fathman CG J Immunol; 2002 Sep; 169(5):2461-5. PubMed ID: 12193715 [TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. Brode S; Raine T; Zaccone P; Cooke A J Immunol; 2006 Nov; 177(10):6603-12. PubMed ID: 17082572 [TBL] [Abstract][Full Text] [Related]
16. Ligand-dependent induction of noninflammatory dendritic cells by anergic invariant NKT cells minimizes autoimmune inflammation. Wang J; Cho S; Ueno A; Cheng L; Xu BY; Desrosiers MD; Shi Y; Yang Y J Immunol; 2008 Aug; 181(4):2438-45. PubMed ID: 18684934 [TBL] [Abstract][Full Text] [Related]
18. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. Bresson D; Fousteri G; Manenkova Y; Croft M; von Herrath M J Autoimmun; 2011 Dec; 37(4):342-51. PubMed ID: 22063316 [TBL] [Abstract][Full Text] [Related]
19. Plasmacytoid dendritic cells license regulatory T cells, upon iNKT-cell stimulation, to prevent autoimmune diabetes. Beaudoin L; Diana J; Ghazarian L; Simoni Y; Boitard C; Lehuen A Eur J Immunol; 2014 May; 44(5):1454-66. PubMed ID: 24481989 [TBL] [Abstract][Full Text] [Related]
20. Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes. Chen YG; Choisy-Rossi CM; Holl TM; Chapman HD; Besra GS; Porcelli SA; Shaffer DJ; Roopenian D; Wilson SB; Serreze DV J Immunol; 2005 Feb; 174(3):1196-204. PubMed ID: 15661873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]